Coming soon – Biotechnology Entrepreneurship: From Science to Solutions

Coming soon, a book by Michael L. Salgaller, PhD. In this new book — Biotechnology Entrepreneurship: From Science to Solutions — Michael combines the voices of a diverse set of industry insiders with extensive experience in biotechnology commercialization to prepares nascent founders, managers, investors, and other biotechnology company stakeholders to position themselves and their companies […]


Synthetic Biology: Revolutionary or Evolutionary

Synthetic biology has been hailed as a revolution in biotechnology, enabling bold new possibilities in areas such as energy production, medicines, and other applications. But, is it really revolutionary, or just a new tool? With our current knowledge of the structure and function of proteins, the ability for de novo engineering is relatively limited. The […]


Broad Institute acquires license to all ChemAxon products and deploys across Chemical Biology Platform.

Compound registration, structure search and computed properties rolled out. Budapest, Hungary and Cambridge, Massachusetts, 19 August 2010 – ChemAxon, a leading provider of chemistry software for life sciences, announced today that they have entered into an agreement with the Broad Institute of Harvard and MIT, which will license ChemAxon’s platform, discovery toolkits and desktop applications […]


BiondVax Announces Receipt of Ethics (“Helsinki”) Committee Approvals for the Initiation of first Phase II Clinical Trial for Universal Influenza Vaccine

Ness Ziona, Israel –  17 August 2010 – BiondVax Pharmaceuticals Ltd. (TASE: BNDX), an Israeli biopharmaceutical company at the forefront of global efforts towards the development of a universal influenza vaccine, today announced that it has received the approvals of the Ethics (“Helsinki”) Committees of the Institutional Review Boards (IRB) of both the Hadassah Clinical […]


Headwaters MB Adds to Life Sciences Team

Headwaters MB announced that Don Warriner and Brad Rosborough have joined the firm as Managing Directors within the Life Sciences practice. Don Warriner joined Headwaters from Venture West Partners where he was focused on capital formation, sell-side and buy-side opportunities in software / technology companies.  Don previously was an executive at IBM and the CEO […]


Drug inventor report profiles individuals, US states, and countries leading pharmaceutical innovation

A new report from DrugPatentWatch.com profiles the leading researchers, US states, and countries responsible for drugs approved over the past ten years. The report features: Top Inventors Which inventors were granted the most patents? Patents per Inventor The patents awarded to each inventor Approved Drugs per Inventor The approved drugs protected by each inventor’s patents […]


Drug Patent Expirations in August 2010

Drug Patent Expirations in August 2010 Tradename Applicant Generic Name Patent Number Patent Expiration ATRIPLA Gilead efavirenz; emtricitabine; tenofovir disoproxil fumarate 7,402,588*PED Aug 1, 2010 TRUVADA Gilead emtricitabine; tenofovir disoproxil fumarate 7,402,588*PED Aug 1, 2010 EMTRIVA Gilead emtricitabine 7,402,588*PED Aug 1, 2010 GENESA Gensia Automedics arbutamine hydrochloride 5,234,404 Aug 10, 2010 PREVPAC Takeda Pharms Na […]


Synthetic Biology: What's the Agenda?

The Center for Policy on Emerging Technologies, where I am on the board of directors, is hosting an Emerging Technologies Roundtable: August 13, 2010 – “Synthetic Biology: What’s the Agenda?” Synthetic biology has hit the headlines yet again. The J. Craig Venter Institute’s recent dramatic announcement led to a replay of President Clinton’s urgent request […]


Do NOT follow this link or you will be banned from the site!